Viewing Study NCT06217757


Ignite Creation Date: 2025-12-24 @ 6:37 PM
Ignite Modification Date: 2026-01-27 @ 3:45 AM
Study NCT ID: NCT06217757
Status: RECRUITING
Last Update Posted: 2024-05-13
First Post: 2024-01-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sponsor: Sichuan University
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lung Cancer View
None Extensive-stage Small-cell Lung Cancer View
Keywords: